SCHEDULE 13G/A: Biotechnology Value Fund Entities Disclose Significant 7.8% Stake in Tyra Biosciences

Multiple entities associated with Biotechnology Value Fund, including Mark N. Lampert, have disclosed a combined beneficial ownership of 7.8% in Tyra Biosciences, Inc. as of December 31, 2024.

Summary

• Biotechnology Value Fund, L.P. and its affiliated entities, including BVF I GP LLC, Biotechnology Value Fund II, L.P., BVF II GP LLC, Biotechnology Value Trading Fund OS LP, BVF Partners OS Ltd., BVF GP Holdings LLC, BVF Partners L.P., BVF Inc., and Mark N. Lampert, have filed an Amendment No. 3 to Schedule 13G regarding their beneficial ownership in Tyra Biosciences, Inc.
• As of December 31, 2024, the aggregate beneficial ownership across all related reporting persons, primarily managed by BVF Partners L.P. and overseen by Mark N. Lampert, totals 3,944,194 shares of Tyra Biosciences' Common Stock.
• This aggregate ownership represents approximately 7.8% of Tyra Biosciences' outstanding shares, based on 50,602,991 shares outstanding as of November 4, 2024.
• Specifically, Biotechnology Value Fund, L.P. beneficially owns 2,032,310 shares (4.0%), Biotechnology Value Fund II, L.P. beneficially owns 1,642,427 shares (3.2%), and Biotechnology Value Trading Fund OS LP beneficially owns 205,920 shares (0.4%).
• The filing indicates that the securities were not acquired for the purpose of changing or influencing control of the issuer, but allows for activities solely in connection with a nomination under Rule 14a-11.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive as a significant stake by a specialized fund can be seen as a vote of confidence, although the document itself is a neutral factual disclosure of ownership.

Positives

• A significant beneficial ownership stake of 7.8% by a specialized biotechnology investment fund (Biotechnology Value Fund entities) indicates a strong conviction or long-term interest in Tyra Biosciences, Inc.
• The filing provides transparency regarding the ownership structure and the various entities under the Biotechnology Value Fund umbrella.

Negatives

• The document, being a beneficial ownership disclosure, does not contain any negative financial or operational information about Tyra Biosciences.

Risks

• The document does not explicitly state risks related to Tyra Biosciences' operations or financial health, as it is solely a disclosure of ownership.

Future Outlook

NA

Industry Context

This Schedule 13G filing indicates a significant investment by a specialized biotechnology fund, Biotechnology Value Fund, in Tyra Biosciences. Such an investment suggests the fund's positive assessment of Tyra Biosciences' potential within the broader biotechnology sector, particularly given the fund's focus on value in this industry.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor's stake may instill confidence and potentially influence market perception of Tyra Biosciences' stock.
• Company Management: A large institutional holder like Biotechnology Value Fund may engage with management on strategic matters, although the filing states the shares are not held for the purpose of changing or influencing control.

Key Dates

Keywords

Tyra Biosciences, Biotechnology Value Fund, Mark N. Lampert, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Institutional Investor, Biotech, Investment Fund